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Abstract
Objective: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly 
administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin®. Local 
tolerability and treatment satisfaction were also assessed.
Design: 26-week randomized, controlled phase 3 safety and tolerability trial in six countries (NCT02382939).
Methods: Male or female patients aged 18–79 years with adult GH deficiency (AGHD), treated with once-daily GH for 
≥6 months, were randomized to once-weekly somapacitan (n = 61) or once-daily Norditropin (n = 31) administered 
subcutaneously by pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth factor I (IGF-I) 
standard deviation score (SDS) levels within the normal range, and then administered at a fixed dose. Outcome 
measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan/anti-GH 
antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for 
Medication-9 (TSQM-9).
Results: Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in both groups. AEs were mostly mild or 
moderate and transient in nature. The most common AEs were nasopharyngitis, headache and fatigue in both groups. 
More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were 
reported. No anti-somapacitan or anti-GH antibodies were detected. The TSQM-9 score for convenience increased 
significantly more with somapacitan vs Norditropin (P = 0.0171).
Conclusions: In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were 
identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin.
Introduction
Adult growth hormone deficiency (AGHD) is characterized 
by several clinical features that compromise general health 
and quality of life. If left untreated, AGHD is associated 
with disturbed lipoprotein metabolism, reduced exercise 
capacity, increased body fat, reduced bone mineral 
density (BMD), increased risk of cardiovascular morbidity 
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and mortality and decreased cognition and psychological 
well-being (1, 2, 3, 4). Treatment of AGHD aims to 
prevent or ameliorate the long-term complications of 
growth hormone deficiency (GHD) and improve quality 
of life (QoL) (1, 3). Human GH replacement has been 
shown to be an effective treatment with regard to these 
aims, with a favorable safety profile, both in randomized 
studies against placebo (reviewed in (2, 5)) and in longer-
term open studies and studies based on records from 
surveillance databases (6, 7).
GH replacement is generally administered by daily 
subcutaneous injections, resulting in a pharmacokinetic 
profile far from the physiological pulsatile pattern of 
endogenous GH secretion. Nevertheless, the safety 
and efficacy of daily GH injections for the treatment 
of adults and children with GHD have been confirmed 
in numerous clinical studies (2). Although daily GH 
is administered with the use of fine needles which 
minimize pain, some patients still find a daily regimen 
burdensome, particularly because treatment may last for 
several years or even be lifelong. It is well established that 
poor adherence with medication is associated with poorer 
clinical outcomes (8). Some studies of patients with 
AGHD have reported poor adherence rates – for example, 
a survey of 158 adult patients who were receiving or had 
received GH therapy rated only 34% as ‘highly compliant’ 
(9), and a recent retrospective single-center cohort study 
classified adherence as <20% in 6.6% of 179 patients with 
AGHD (10). A reduction in the frequency of injections 
could potentially improve adherence and thus clinical 
outcomes.
Somapacitan (Novo Nordisk A/S) is a novel reversible 
albumin-binding GH derivative in which fatty acids 
with non-covalent albumin-binding properties have 
been conjugated by alkylation to GH. The resulting non-
covalent binding of the GH molecule to endogenous 
albumin reduces the clearance and extends the half-life of 
the drug. Pharmacokinetic studies in healthy adults (11) 
and both children (12) and adults with GH deficiency (13) 
showed that the concentration of somapacitan peaked at 
1–2 days after injection and returned to low levels after 
7  days, and pharmacodynamic studies showed Cmax for 
insulin-like growth factor I (IGF-I) and IGF-I SDS4 days 
after dosing, with values subsequently falling gradually, 
supporting the possibility of once-weekly subcutaneous 
administration. A similar technology of using a conjugated 
linker to extend the plasma half-life of a peptide drug has 
previously been used successfully in the development 
of insulin detemir, a long-acting insulin analog (14), 
and liraglutide, a long-acting glucagon-like peptide-1 
(GLP-1) derivative (15) without any associated significant 
tolerability issues. Despite a similar protraction technology 
being applied, somapacitan has a different receptor 
pharmacology and different albumin-binding properties, 
resulting in a longer residual time in circulation compared 
with insulin detemir and liraglutide. This, together with 
the stimulation of the IGF-I secretion, makes somapacitan 
active for a longer interval.
Somapacitan was also shown in short-term trials 
to be well tolerated in healthy adults (11), and both 
children (12) and adults with GH deficiency (13).We now 
report the first data obtained from a trial of somapacitan 
investigating the clinical safety and tolerability of, and 
treatment satisfaction with, once-weekly somapacitan vs 
once-daily GH (Norditropin® FlexPro®, Novo Nordisk A/S) 
over 26 weeks in patients with AGHD previously treated 
with daily GH.
Subjects and methods
Patients
Male or female patients aged 18–79 years diagnosed with 
AGHD and treated with once-daily GH for ≥6 months were 
eligible for the trial. The diagnosis of AGHD could include 
GHD of either adult onset (diagnosed alone or associated 
with multiple hormone deficiencies) or childhood onset. 
The diagnosis of AGHD was made in accordance with the 
GH Research Society guidelines (16), Endocrine Society 
guidelines (1) or relevant guidelines applicable at the time 
of AGHD diagnosis.
Full inclusion and exclusion criteria are shown in 
Supplementary Table  1 (see section on Supplementary 
data given at the end of this article).
Trial design and procedures
This was a multinational, multicenter, randomized, 
open-label, active-controlled trial (ClinicalTrials.gov: 
NCT02382939; REAL 2), conducted at 26 sites in six 
countries between February 2015 and January 2016. The 
protocol was approved by the local and national ethics 
committees, as appropriate and conducted in accordance 
with the International Conference on Harmonisation 
guidelines for Good Clinical Practice (International 
Conference on Harmonisation. Harmonised Tripartite 
Guideline for Good Clinical Practice. Geneva, Switzerland. 
1996. http://www.ich.org/products/guidelines/efficacy/
efficacy-single/article/good-clinical-practice.html 
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(accessed 18 July 2017)) and the Declaration of Helsinki 
(WMA. Declaration of Helsinki: Ethical principles for 
medical research involving human subjects. Last amended 
by the 64th WMA General Assembly (Brazil). Oct 2013. 
https://www.wma.net/policies-post/wma-declaration-
of-helsinki-ethical-principles-for-medical-research-
involving-human-subjects/ (accessed 18 July 2017)). 
Informed consent was obtained from all patients prior to 
inclusion.
Patients were randomized 2:1 to receive once-weekly 
somapacitan or once-daily Norditropin (Supplementary 
Fig.  1). The randomization process is described in the 
Supplementary material. Somapacitan was administered 
at a starting dose of 1.0−1.5 mg/week (2.0 mg/week for 
women on oral estrogen treatment), and Norditropin at 
a starting dose of 0.1−0.2 mg/day (0.3 mg/day for women 
on oral estrogen treatment). Both treatments were 
administered via subcutaneous injection: somapacitan 
was administered in the morning and Norditropin was 
administered in the evening, both using a prefilled 
FlexPro pen.
During the first 8  weeks, somapacitan and 
Norditropin doses were titrated according to serum 
IGF-I standard deviation score (SDS) in order to achieve 
IGF-I levels within the normal range, and preferably 
between 0 and 2 SDS. A fixed dose was administered for 
the remaining 18-week period. Sampling of IGF-I during 
the titration phase was planned at Day 3–4, where the 
IGF-I value was expected to represent the average IGF-I 
value during the week. Maximum recommended doses 
were somapacitan 8.0 mg/week or Norditropin 1.1 mg/
day (1.0 mg/day in Japan). Somapacitan doses of greater 
than 4 mg were split into two injections of equal volume 
(required for nine patients).
Two washout periods were included for the purpose 
of measuring antibodies: a 1-day washout before 
randomization and a 1-week washout after Week 26 
(Supplementary Fig. 1).
During the trial period, patients were instructed by 
the site staff to record dose adherence (date and time of 
each dose of trial product as well as any missed dose). 
Adherence (%) was calculated as the number of reported 
doses from patient diaries and doses administered 
during clinic visits, divided by number of planned doses, 
multiplied by 100.
Safety assessments
Safety was assessed in terms of the incidence of AEs, 
including injection site reactions, from baseline to the end 
of the post-treatment follow-up period (1 week after end 
of treatment). All AEs either observed by the investigator, 
reported spontaneously by the patients, or reported in 
response to questioning at each site visit, were recorded 
and evaluated. Injection site reactions were evaluated at 
each visit by manual, visual inspection of injection sites 
and assessment of the occurrence of pain, tenderness, 
itching, rash, redness, induration and any other signs of 
injection site reactions. Injection site reactions could also 
be reported by the patient between visits.
Other safety assessments included physical 
examination, body weight, vital signs, electrocardiograms, 
clinical laboratory tests (hematology, biochemistry, 
urinalysis, fasting blood glucose and fasting blood insulin) 
and the occurrence of anti-somapacitan or anti-GH 
antibodies. Samples for glucose and insulin were taken 
on the same day as dosing with somapacitan (Week 8) or 
4 days after dosing with somapacitan (Weeks 16 and 25).
Treatment satisfaction
The change in treatment satisfaction from randomization 
to Week 26 was assessed using the Treatment Satisfaction 
Questionnaire for Medication-9 (TSQM-9) (17). The 
original TSQM-14 was shown to be a psychometrically 
sound and valid measure of the major dimensions of 
satisfaction with medication in patients with different 
chronic diseases (18). An abbreviated version that omitted 
questions on side effects, the TSQM-9, was subsequently 
also validated (17). Items on the TSQM-9 are rated on a 
5- or 7-point scale, with an increase in scores signifying an 
increase in treatment satisfaction and can be grouped to 
provide effectiveness, convenience and global satisfaction 
scores. Questionnaires were completed by the patients, 
without assistance from site personnel, at randomization 
and at Weeks 16 and 26.
Assay methods
Analysis of serum IGF-I and insulin-like growth factor-
binding protein-3 (IGFBP-3) concentration was performed 
using commercially available assay kits (Immuno 
Diagnostic Systems immunoassay ISYS assay at the 
analytical central laboratory PPD Global Central Labs, 
BVBA, Zaventem, Belgium). Somapacitan was dosed on 
Day 1 of each week and samples for serum IGF-I analysis 
were taken on Day 4, except for Week 4, when samples 
were taken on Day 7 in order to establish the trough level. 
IGF-I and IGFBP-3 assay performance was in accordance 
with the assay information provided by the manufacturer. 
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The IGF-I assay was calibrated using World Health 
Organization International Standard 02/254 and IGF-I 
SDSs were calculated according to Bidlingmaier et al. (19).
Anti-somapacitan and anti-GH antibodies were also 
assessed, using validated bridging ELISAs developed by 
Novo Nordisk to specifically determine antibody levels 
against somapacitan and human GH, respectively (for 
details see (13)).
Statistical analysis
The sample size was not based on any formal calculations 
apart from accounting for withdrawals in the final 
sample size. Based on, at most, 15% withdrawals per 
treatment arm, it was estimated that 90 patients should 
be randomized in a 2:1 ratio between somapacitan and 
Norditropin. The 15% withdrawal rate was considered 
conservative and acceptable relative to other trials with 
similar trial designs, in particular considering that this 
trial had no placebo arm and did not include any invasive 
or unpleasant investigations.
The safety analysis and full analysis sets both included 
all randomized subjects who received at least one dose of 
treatment. The primary endpoint and all safety endpoints 
were reported by descriptive statistics.
Estimated treatment differences in TSQM-9 
effectiveness, convenience and global satisfaction scores 
at 26  weeks were estimated from a mixed model for 
repeated measurements, with treatment, GHD onset type, 
sex, region and sex by region interaction term as factors 
and baseline as a covariate, all nested within week as a 
factor. Patients without post-randomization data for the 
analyzed endpoint were not included in the analysis.
Results
Patient disposition
Of 98 screened patients, 92 were randomized to 
receive once-weekly somapacitan (n = 61) or once-daily 
Norditropin (n = 31). Characteristics of the randomized 
patients were well matched at baseline (Table 1). All 92 
AGHD patients were included in the full analysis set and 
the safety analysis set, which were identical.
All randomized patients were exposed to their 
assigned treatment, and 86 patients completed the 
trial. Three patients in each treatment group withdrew 
(somapacitan: 4.9%; Norditropin: 9.7%). In each arm, 
two patients withdrew consent to participate in the 
trial, and one patient withdrew due to AEs as follows: 
for somapacitan: asthenia and disturbance in attention; 
and for Norditropin, asthenia, somnolence, disturbance 
in attention and headache. One participant discontinued 
somapacitan treatment due to travel abroad without 
withdrawing from the trial.
Dosing
After the dose titration period, the mean somapacitan dose 
(SD) was 1.96 (1.45) mg/week in the 18 weeks of fixed-
dose treatment, compared with a starting dose of 1.5 mg/
week. For Norditropin, the mean dose after titration was 
0.20 (0.14) mg/day, which was similar to the starting dose.
The mean days of exposure were similar in the two 
groups: 177 (range: 7–196) days for somapacitan and 172 
(10–184) days for Norditropin.
Mean treatment adherence by patients during the 
trial, measured as defined previously under Trial Design 
Table 1 Baseline characteristics.
Somapacitan once-weekly (n = 61) Norditropin once-daily (n = 31)
Age (years), mean (s.d.) 48.1 (16.2) 51.7 (17.1)
Female, n (%) 28 (45.9) 14 (45.2)
Race, n (%)
  Asian 12 (19.7) 6 (19.4)
  White 36 (59.0) 18 (58.1)
  Not available 13 (21.3) 7 (22.6)
Body weight (kg), mean (s.d.) 82.1 (17.6) 81.0 (21.8)
BMI (kg/m2), mean (s.d.) 28.6 (5.0) 28.5 (5.6)
GHD onset, n (%)
  Childhood – idiopathic 6 (9.8) 3 (9.7)
  Childhood – organic 18 (29.5) 7 (22.6)
  Adulthood 37 (60.7) 21 (67.7)
IGF-I SDS 0.28 (1.50) 0.91 (1.24)
GH dose level at screening (mg), mean (s.d.) 0.5 (0.3) 0.5 (0.9)
BMI, body mass index; GH, grouwth hormone; GHD, growth hormone deficiency; SDS, standard deviation score.
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and Procedures (i.e. percentage of doses taken correctly), 
was 93.1% (range: 3.8–100.0%) in the somapacitan group 
and 90.4% (5.6–100.0%) in the Norditropin group.
IGF-I levels
Mean IGF-I SDS values were maintained throughout the 
trial, remaining between 0 and 2 SDS in both treatment 
groups. At the end of trial, IGF-I SDS values were similar 
in the two groups: mean (s.d.) 0.22 (0.89) for somapacitan 
and 0.35 (0.82) for Norditropin (Fig.  1). No IGF-I SDS 
mean values were above +2 in the fixed-dose treatment 
period. The initially wide range in IGF-I SDS scores tended 
to decrease during the trial (somapacitan: range from 
–4.23; 2.80 to –2.73; 1.65; Norditropin: range from –1.63; 
3.10 to –1.51; 1.81). Individual IGF-I SDS values above +2 
were observed only in the titration period (somapacitan: 
seven of 61 patients; Norditropin: four of 31 patients).
Safety
AEs and serious AEs (SAEs)
AEs were reported by 86.9% and 67.7% of patients in 
the somapacitan and Norditropin groups, respectively. 
Rates of AEs per 100 patient-years of exposure were 514.2 
and 530.8, respectively (Table  2). One patient in each 
treatment group withdrew due to AEs.
The reported AEs were similar overall to AEs observed 
in previous trials with daily human GH (hGH) treatment, 
with nasopharyngitis, headache and fatigue as the most 
frequently occurring AEs for both somapacitan and 
Norditropin (Table 3); no cases of headache were related 
to intracranial hypertension as assessed by clinical 
investigators. The majority of AEs were single events 
reported in one or two patients and of mild/moderate 
severity. The most frequent AEs were reported with a 
greater frequency and event rate in the Norditropin group 
than in the somapacitan group. There were no reports 
of peripheral edema during treatment. Carpel tunnel 
syndrome was reported as a concomitant illness in one 
patient at baseline.
SAEs (n = 7) were reported as follows: in the somapacitan 
group, cholelithiasis, procedural complication, 
mammoplasty and patella fracture (all n = 1 event in one 
patient each); and in the Norditropin group, intestinal 
ischemia and short-bowel syndrome (n = 2 events, 
2.0
IG
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–0.5
–1.0
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26
Norditropin®
Somapacitan
Figure 1
Serum IGF-I SDS levels (mean + s.e.m.) vs time. *Week 4 is the 
trough value, measured before administration of 
somapacitan. SDS, standard deviation score.
Table 2 Adverse events.
 
 
Somapacitan  
once-weekly (n = 61)
Norditropin  
once-daily (n = 31)
n (%) E Rate n (%) E Rate
Adverse 
events
53 (86.9) 159 514.2 21 (67.7) 81 530.8
Serious 
adverse 
events
4 (6.6) 4 12.9 2 (6.5) 3 19.7
Severity
  Mild 44 (72.1) 119 384.8 18 (58.1) 58 380.1
  Moderate 16 (26.2) 32 103.5 8 (25.8) 19 124.5
  Severe 5 (8.2) 8 25.9 2 (6.5) 4 26.2
Relationship to trial drug
  Unlikely 
related
46 (75.4) 130 420.4 21 (67.7) 68 445.6
  Possibly 
related
9 (14.8) 15 48.5 3 (9.7) 5 32.8
  Probably 
related
8 (13.1) 14 45.3 4 (12.9) 8 52.4 
E, number of adverse events; n, number of patients with adverse events; 
Rate, adverse event rate/100 patient-years.
Table 3 Adverse events occurring in ≥5% of patients in 
either treatment group.
 Somapacitan Norditropin
% Rate % Rate
Nasopharyngitis 19.7 42.0 25.8 72.1
Headache 11.5 35.6 19.4 65.5
Fatigue 9.8 22.6 16.1 32.8
Dizziness 1.6 3.2 9.7 19.7
Arthralgia 8.2 16.2 6.5 13.1
Abdominal pain 6.6 12.9 0.0 0.0
Asthenia 6.6 16.2 3.2 6.6
Sciatica 6.6 12.9 0.0 0.0
Depression 0.0 0.0 6.5 13.1
Gamma-glutamyltransferase 
increased
0.0 0.0 6.5 13.1
Central hypothyroidism 
(secondary)
1.6 3.2 6.5 13.1 
Rate, event rate/100 patient-years.
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both in one patient) and nephrolithiasis (n = 1 event in 
one patient). The ‘procedural complication’ refers to a 
patient who withdrew after 1 week in the trial following 
complications of a pre-planned meniscus operation and 
was lost to follow-up. All patients recovered from their 
SAE, except the patient with procedural complications 
who was lost to follow-up. All SAEs were judged unlikely 
to be related to trial product by the investigator. There 
were no changes in individual doses due to the SAEs, and 
no SAEs that led to withdrawal.
The most frequent AEs assessed as possibly/probably 
drug related in the somapacitan group were fatigue (five 
patients), asthenia (three patients) and weight increase 
(three patients) and in the Norditropin group, fatigue 
(four patients). Other AEs assessed as possibly/probably 
drug related were reported in only one or two patients in 
each group.
No clinically relevant changes were observed upon 
physical examination or in body weight, vital signs, 
electrocardiograms or clinical laboratory measurements.
Fasting plasma glucose remained stable (Fig.  2A), 
and no new cases of diabetes were reported during the 
trial. There were no changes in the mean glycosylated 
hemoglobin (HbA1c), which was similar across the 
treatment groups. There was some variation in fasting 
insulin during the trial (Fig. 2B).
Local tolerability
The total number of injections in the somapacitan arm was 
more than 1500. No injection site reactions were reported 
that were considered to be clinically significant. Two 
mild and transient injection site reactions were observed 
in patients treated with somapacitan: hematoma in one 
patient after the third dose and bruising in one patient 
after the second dose. No injection site reactions were 
reported with Norditropin. There were no observations of 
lipoatrophy or lipohypertrophy in any patients.
Antibodies
No anti-somapacitan or anti-GH antibodies were detected.
Treatment satisfaction
At baseline, the patients’ evaluation of the effectiveness 
and convenience of the treatment appeared similar in the 
two treatment arms, and global treatment satisfaction 
appeared slightly greater in the daily Norditropin arm 
(not tested for significance) (Supplementary Table 2).
All three categories of TSQM-9 scores (effectiveness, 
convenience, satisfaction) increased from baseline 
to Week 26 (Supplementary Table  2). The mean (s.d.) 
TSQM-9 score for convenience increased by 15.3 (20.9) 
from 68.3 (18.3) at baseline to 83.8 (12.9) at the end of 
trial for somapacitan, and by 3.0 (16.5) from 71.7 (17.5) 
to 75.8 (19.1) with Norditropin. The between-treatment 
difference at the end of trial was statistically significant 
(P = 0.0171) (Fig.  3). The changes in effectiveness and 
treatment satisfaction scores did not differ significantly 
between somapacitan and Norditropin after 26 weeks of 
treatment (Fig. 3). Thus, after 26 weeks of treatment, once-
weekly somapacitan was considered more convenient 
than daily Norditropin.
Discussion
In this 26-week randomized study, multiple doses of once-
weekly somapacitan were well tolerated; no clinically 
significant safety or local tolerability issues (including 
injection site reactions) were reported and the safety 
profile was very similar to that of daily GH. Dose titration 
achieved mean IGF-I SDS values of between 0 and 2 SDS 
Figure 2
(A) Fasting plasma glucose values and (B) fasting plasma 
insulin vs time. Values are mean + s.e.m.
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in both treatment groups. The evaluation of treatment 
satisfaction revealed that patients rated once-weekly 
somapacitan injections as more convenient than once-
daily GH injections.
Somapacitan is a novel GH derivative that binds 
reversibly to endogenous albumin, thus extending its half-
life. The safety profile reported in this trial was similar to 
that observed in previous short-term trials of somapacitan 
in healthy adults (11) and in adults with AGHD (13). Most 
events were mild or moderate and transient in nature. 
Furthermore, the most common AEs, and those judged 
to be probably/possibly drug-related by the investigator, 
were AEs that are commonly observed in GH-treated 
AGHD patients, such as headache, fatigue and asthenia (5). 
Notably, no clinically significant injection site reactions 
were reported. This is reassuring because some previous 
attempts to develop long-acting GH treatments have been 
hampered by local tolerability problems (20). These have 
included lipoatrophy with a pegylated formulation (21), 
nodules and post-injection pain with a sustained-release 
formulation based on microspheres (22), injection site 
reactions with a sustained-release formulation (23) and 
injection site pain in approximately 50% of patients with 
a GH molecule fused to long-chain amino acids (24).
GH affects insulin sensitivity and may therefore 
adversely affect glucose metabolism (7, 25); hence, special 
attention on the effects of GH on glucose metabolism is 
warranted. In the current study, fasting plasma glucose 
levels, fasting insulin levels and HbA1c values did not 
increase markedly over the 26 weeks of the trial, and no 
cases of diabetes were diagnosed. These results are in line 
with a recent analysis of real-life data from patients with 
AGHD, which showed that, in most patients, glucose 
homeostasis was not adversely affected after 4  years of 
daily GH treatment (26). It has been reported that insulin 
resistance is present in adult patients with AGHD and that 
this is worsened by treatment with GH (25). It has also 
been suggested that the favorable effects of long-term GH 
therapy on body composition may counteract the direct 
insulin antagonistic effects (25).
The IGF-I SDS profile was maintained throughout 
the trial in both treatment groups, with mean values of 
between 0 and +2 SDS. IGF-I SDS values >2 were observed 
in only a few patients, in similar proportions in the 
somapacitan and Norditropin groups, and only during 
the titration phase. The decrease in the range of IGF-I 
SDS values during the trial may reflect the effect of the 
titration. These results support once-weekly dosing of 
somapacitan in patients with AGHD and indicate that 
the dose titration used was safe and efficient for male and 
female adult patients (with a modification for women on 
oral estrogen treatment, as described in the Materials and 
methods section).
In this trial, patient satisfaction was assessed using the 
TSQM-9. The change in the TSQM-9 convenience score from 
randomization to Week 26 was statistically significantly 
greater with somapacitan than with Norditropin. Changes 
in effectiveness and satisfaction were numerically greater 
with somapacitan than with Norditropin, but the differences 
did not reach statistical significance. This finding is in line 
with reports of patient preference for weekly rather than 
daily drug administration from other disease areas such as 
osteoporosis (27) and diabetes (28).
To our knowledge, no published studies are available 
comparing adherence rates with once-weekly injections 
vs once-daily injections. In the current trial, adherence 
with therapy, measured as the percentage of correct doses 
taken, was high: 93.1% with somapacitan and 90.4% with 
Norditropin. Adherence was thus very similar between 
the groups, possibly as a result of the controlled nature of 
the clinical trial, with regular clinic visits and assessments, 
as well as highly motivated participating patients. These 
factors may have contributed to rates of adherence higher 
than those reported in real life in adults with GHD 
receiving daily injections (9, 10). We can only speculate 
that, if the greater convenience of a once-weekly regimen 
translates into increased adherence with therapy in real-
life conditions, this could help maximize the efficacy of 
long-term GH replacement.
Limitations of this trial are the fact that efficacy was 
not measured through clinical outcomes, such as changes 
in body composition and quality of life, as the patients 
were already receiving long-term stable GH treatment 
before entering the study. On the other hand, study 
Figure 3
Estimated treatment difference in change in TSQM-9 scores at 
Week 26. Full analysis set. Estimates are from a mixed model 
for repeated measurements. LCL, lower confidence limit; 
TSQM-9, Treatment Satisfaction Questionnaire for 
Medication-9; UCL, upper confidence limit.
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strengths lie in the fact that it was a randomized trial in 
which somapacitan was compared head to head with hGH 
in AGHD patients already using daily GH replacement 
treatment. Thus, the current study adds important data 
for patients who will switch from daily to weekly therapy. 
The patients who were enrolled were well characterized, 
included both sexes and were recruited from several 
centers in five different European countries and Japan, 
thus increasing the generalizability of the results to real-
life clinical practice.
In conclusion, in this 26-week trial in patients with 
AGHD already receiving stable replacement therapy with 
daily GH, the switch to somapacitan was well tolerated and 
stable serum IGF-I concentrations within the normal range 
were achieved. Clinically significant safety issues were 
not identified, nor were any immunogenicity concerns 
revealed. In addition, treatment satisfaction responses 
revealed that the patients considered once-weekly 
somapacitan injections more convenient than once-daily 
GH injections and adherence to treatment was high.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EJE-17-1073.
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